Madrona Ventures has acquired the Obesity treatment’s European patent and the pending American patent application.
Reportedly, the company will be starting the phase II double-blind placebo-controlled clinical trial in Finland. The trial will last for six months.
The safe and effective treatment is a proprietary patented pharmaceutical medicine-based behaviour program by David Sinclair, who has already designed a similar treatment program that has shown results in the treatment of alcoholism.
Dr. Sinclair has now refined this method to provide a precise treatment of eating disorders. The program weakens and removes unhealthy eating habits while simultaneously preserving and reinforcing healthy eating behaviours, exercising, and other calorie-burning activities.